SNCAIP: A Potential Drug Target for Cell Proliferation, Differentiation and Survival

Target Name: SNCAIP

NCBI ID: G9627

SNCAIP

SNCAIP: A Potential Drug Target for Cell Proliferation, Differentiation and Survival

SNCAIP, or Synphilin-1 (isoform 1), is a protein that is expressed in various tissues throughout the body. It is a member of the serine/threonine protein kinase (SPPK) family and is involved in the regulation of cell proliferation, differentiation, and survival.

SNCAIP has been identified as a potential drug target and is currently being investigated as a potential therapeutic approach for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of SNCAIP is its role in the regulation of cell proliferation. SNCAIP has been shown to play a negative role in the regulation of cell growth and has been shown to promote cell cycle arrest and apoptosis in various cell types. This suggests that SNCAIP may be an effective target for drugs that are designed to inhibit cell proliferation.

Another potential mechanism by which SNCAIP may be targeted is its role in the regulation of cell differentiation. SNCAIP has been shown to play a positive role in the regulation of cell differentiation and has been shown to promote the maintenance of stem cell properties in various cell types. This suggests that SNCAIP may be an effective target for drugs that are designed to promote or inhibit stem cell differentiation.

SNCAIP has also been shown to play a role in the regulation of cell survival. SNCAIP has been shown to promote the survival of various cell types and has been shown to protect cells from various forms of stress, such as oxidative stress and mechanical stress. This suggests that SNCAIP may be an effective target for drugs that are designed to promote or inhibit cell survival.

In addition to its role in cell proliferation, SNCAIP has also been shown to play a role in the regulation of cellular signaling pathways. SNCAIP is a component of several signaling pathways, including the PI3K/Akt signaling pathway and the TGF-β signaling pathway. These signaling pathways are involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.

Given its involvement in a variety of cellular processes, SNCAIP is an attractive target for drug development. Researchers are currently working to identify small molecules that can inhibit the activity of SNCAIP and to determine the mechanisms by which these molecules will interact with SNCAIP.

While the development of drugs that target SNCAIP is still in its early stages, it is clear that SNCAIP is a promising drug target with potential for the treatment of a variety of diseases. Further research is needed to fully understand the role of SNCAIP in cellular processes and to identify effective small molecules that can inhibit its activity.

Protein Name: Synuclein Alpha Interacting Protein

Functions: Isoform 2 inhibits the ubiquitin ligase activity of SIAH1 and inhibits proteasomal degradation of target proteins. Isoform 2 inhibits autoubiquitination and proteasomal degradation of SIAH1, and thereby increases cellular levels of SIAH. Isoform 2 modulates SNCA monoubiquitination by SIAH1

The "SNCAIP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNCAIP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets